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Abstract
Chlamydia trachomatis remains one of the few major human pathogens for which there is no transformation system. C.
trachomatis has a unique obligate intracellular developmental cycle. The extracellular infectious elementary body (EB) is an
infectious, electron-dense structure that, following host cell infection, differentiates into a non-infectious replicative form
known as a reticulate body (RB). Host cells infected by C. trachomatis that are treated with penicillin are not lysed because
this antibiotic prevents the maturation of RBs into EBs. Instead the RBs fail to divide although DNA replication continues. We
have exploited these observations to develop a transformation protocol based on expression of b-lactamase that utilizes
rescue from the penicillin-induced phenotype. We constructed a vector which carries both the chlamydial endogenous
plasmid and an E.coli plasmid origin of replication so that it can shuttle between these two bacterial recipients. The vector,
when introduced into C. trachomatis L2 under selection conditions, cures the endogenous chlamydial plasmid. We have
shown that foreign promoters operate in vivo in C. trachomatis and that active b-lactamase and chloramphenicol acetyl
transferase are expressed. To demonstrate the technology we have isolated chlamydial transformants that express the
green fluorescent protein (GFP). As proof of principle, we have shown that manipulation of chlamydial biochemistry is
possible by transformation of a plasmid-free C. trachomatis recipient strain. The acquisition of the plasmid restores the
ability of the plasmid-free C. trachomatis to synthesise and accumulate glycogen within inclusions. These findings pave the
way for a comprehensive genetic study on chlamydial gene function that has hitherto not been possible. Application of this
technology avoids the use of therapeutic antibiotics and therefore the procedures do not require high level containment
and will allow the analysis of genome function by complementation.
Citation:Wang Y, Kahane S, Cutcliffe LT, Skilton RJ, Lambden PR, et al. (2011) Development of a Transformation System for Chlamydia trachomatis: Restoration of
Glycogen Biosynthesis by Acquisition of a Plasmid Shuttle Vector. PLoS Pathog 7(9): e1002258. doi:10.1371/journal.ppat.1002258
Editor: Raphael H. Valdivia, Duke University, United States of America
Received March 7, 2011; Accepted July 26, 2011; Published September 22, 2011
Copyright:  2011 Wang et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This work was funded by Grant no 091296 from the Wellcome Trust. http://www.wellcome.ac.uk/ The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: inc@soton.ac.uk
Introduction
C. trachomatis is a major human pathogen with a unique
intracellular developmental cycle [1,2]. This cycle begins when the
extracellular, infectious form of the microorganism, the EB, binds
to susceptible host cells [3,4]. EBs are taken up into a phagocytic
vesicle which is modified to become a chlamydial inclusion where
individual EBs differentiate into the metabolically active, replica-
tive form of the microorganism, the RB [5]. RBs divide by binary
fission and, when 8–10 divisions have elapsed, they differentiate
back into EBs that are released by cell lysis [6].
C. trachomatis has a small and highly conserved genome of some
1,000 kb [7]. In addition, most C. trachomatis isolates carry a
plasmid of 7.5kb [8] which encodes eight genes. All eight genes are
transcribed [9] and translated during the developmental cycle
[10]. Despite the availability of the plasmid as a potential vector,
the development of a simple robust genetic transformation system
for the chlamydiae has remained a significant challenge [11]. The
demand for such a system is evidenced by the recent development
of a means to mutate the C. trachomatis chromosome [12] but to
reach its full potential this requires a complementary gene transfer
system. An approach using chromosomal integration was used to
make recombinants in C. psittaci EBs by allelic exchange using
exogenous DNA introduced by electroporation [13]. This was
limited to the 16S rDNA region and only allowed integration of a
short 1 kb marker at extremely low efficiencies. C. psittaci requires
high levels of containment and therefore is not readily available to
the wider research community. Electroporation of EBs was used in
1994 in an attempt to transform C. trachomatis with an episomal
vector based on the chlamydial plasmid [14]. No stable
transformants were isolated although inclusions were present for
up to four passages under chloramphenicol selection. There have
been reports of plasmid free strains of C. trachomatis but only three
viable, naturally occurring plasmid-free isolates of C. trachomatis
have been described [15–17], thus most C. trachomatis isolates carry
the 7.5 kbp plasmid, its biological function is unknown although its
presence has for a long time been linked to the ability of C.
trachomatis to synthesise glycogen [18]. We tried unsuccessfully to
cure a lymphogranuloma venereum (LGV) strain of C. trachomatis
L2 of its plasmid [19] but recently curing of the plasmid from a
genital tract C. trachomatis D has been described [20]. This plasmid-
cured strain and the naturally occurring plasmid-free strains do
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not stain for glycogen [21]; the plasmid does not encode glycogen
synthesis genes thus the phenomenon involves complex interac-
tion(s) between the plasmid and the chlamydial genome to elicit
the glycogen staining phenotype [22]. However, formal proof
associating this property with the plasmid alone is necessary but
can only be achieved by re-introducing the plasmid into a plasmid-
free strain. This has not been possible because of the absence of a
means to genetically manipulate C. trachomatis.
We report here the first successful development of a simple,
robust, reproducible plasmid-based genetic transformation system
for C. trachomatis using penicillin selection and calcium chloride
(CaCl2) treatment of EBs to render them competent. Penicillin
causes C. trachomatis to enter a persistent non-infectious state [6,23–
25]; therefore our experimental plan was to select genetically stable,
penicillin-resistant transformants by recovery of Chlamydiae from
penicillin-arrested division. To demonstrate the effectiveness and
reproducibility of the procedure, we have engineered a strain of C.
trachomatis that is penicillin resistant and that expresses GFP. We
have also proven the role of the chlamydial plasmid in glycogen
biosynthesis by re-introducing the plasmid into a C. trachomatis strain
that is plasmid-free (C. trachomatis L2 (25667R)) [15]. We have
demonstrated that as a result of this genetic transformation the
previously plasmid-free strain C. trachomatis L2 (25667R) acquired
the ability to synthesize and accumulate glycogen within inclusions.
Results/Discussion
Our primary aim was to develop a transformation protocol using
a chlamydial plasmid-based shuttle vector. Our scientific aim was to
determine whether glycogen biosynthesis, a distinctive characteristic
of C. trachomatis which has been linked to the presence of the
plasmid, could be restored in a plasmid-free, glycogen-free variant
of C. trachomatis, by re-introducing the plasmid DNA.
Plasmid shuttle vector - design and choice of selectable
marker(s)
To enable the selection of transformants for plasmid vectors,
antibiotic resistance markers offer the most attractive choices. There
are a range of single gene antibiotic resistance markers that are safely
used worldwide for the routine and stable transformation of bacteria.
These markers are popular because it is not possible to generate
transformants unless an intact gene is acquired thus eliminating the
problem of background resistance through spontaneous mutation.
The markers used in routine selection of bacterial transformants
include tetracycline resistance, chloramphenicol resistance and b-
lactamase (penicillin/ampicillin resistance) [26]. Tetracycline resis-
tance markers have been used in allelic transfer experiments for
chlamydiae [27], but tetracycline is a controversial choice because it is
used routinely to treat C. trachomatis infections [28]. C. trachomatis is
sensitive to chloramphenicol but it is difficult to reproduce a minimal
inhibitory assay as this antibiotic causes mitochondrial stress [29]
limiting chlamydial growth and is thus not so useful for selection and
continuous passaging of transformants. By contrast, the effects of
penicillin on C. trachomatis are well studied [6,25], it is bacteriostatic
giving a resistant phenotype and penicillin is not recommended for
the treatment of chlamydial infections [30]. Following penicillin
treatment, the developmental cycle is slowed and the transition to EBs
ceases with the formation of giant, aberrant RBs. The normal
developmental cycle resumes upon removal of penicillin (at low
concentrations) from the culture media and the resultant normal
chlamydial inclusions are easily detectable by phase contrast
microscopy [6]. We reasoned that rescue of infectious C. trachomatis
from the penicillin-induced aberrant developmental cycle through
transformation and b-lactamase expression would present a distinc-
tive phenotype that could be easily selected microscopically and
transformants could be recovered under penicillin selection. We
tested a range of penicillin concentrations on the growth of normal C.
trachomatis L2 and determined that 10 units/ml of penicillin was a
suitable concentration for inhibition of C. trachomatis and hence this
was the antibiotic concentration chosen for the C. trachomatis
transformation work. Penicillin resistance was introduced into a C.
trachomatis plasmid (pL2) by ligating a pBR325 plasmid and the pL2
plasmid (pBR325::L2). This was a simple, standard recombinant
plasmid from our collection that had an intact b-lactamase gene and
the complete chlamydial plasmid. Ligation into the Bam HI site of
pBR325 plasmid created an insertional inactivation of the tet gene but
still conferred penicillin and chloramphenicol resistance. The BamHI
site in the pL2 plasmid is located in coding sequence 1 (CDS1), a
region which is susceptible to mutation/deletion without affecting
plasmid stability [8,19]. The plasmid map is shown in Figure 1.
Strains of C. trachomatis
We chose the well-studied, laboratory-adapted strain C.
trachomatis L2/434/Bu (ATCC VR902B) as the recipient strain
because we already had a full complement of biological and
genetic information for this strain (the complete genome sequence
and defined proteome) [31,32]. The vector with which we started
the work contained the cognate pL2 plasmid cloned from C.
trachomatis L2/434/Bu genomic DNA [33]. Furthermore, the LGV
strains [34] that we used: C. trachomatis L2/434/Bu and (later) the
plasmid-free C. trachomatis L2 (25667R) have relatively low particle
to infectivity ratios [35] and do not need centrifugation to achieve
efficient cell infection, thus these bacteria have a higher viability
than standard genital tract isolates and have a faster developmen-
tal cycle giving a quicker turn around of experiments [4].
Transformation of C. trachomatis L2/434/Bu
We wanted to investigate whether it was possible to transform
EBs using a simple standard protocol and a defined buffer that
could be reproduced in any laboratory. Standard bacterial
transformations are based on the primary observation that
bacteria treated with ice cold solutions of CaCl2 followed by
Author Summary
C. trachomatis is a major human pathogen for which there
is no means of genetically manipulating its DNA. It is an
obligate intracellular bacterium which has a complex
developmental cycle that takes place in a specialized host
cell cytoplasmic vacuole known as an inclusion. We have
constructed a shuttle vector based on the chlamydial
plasmid and developed a new approach to select
genetically modified bacteria. It uses rescue by selection
of stable infectious, penicillin-resistant C. trachomatis from
a pool of non-dividing, non-infectious C. trachomatis
(induced by penicillin arrest of the developmental cycle).
The transformed C. trachomatis is also cured of its
endogenous plasmid by the selection of the transforming
vector. The vector was modified to express the green
fluorescent protein (GFP) in both Chlamydia and E. coli. We
have genetically manipulated a plasmid-free recipient
strain of C. trachomatis and shown restoration of the
ability of this recipient strain to synthesize and accumulate
glycogen within inclusions upon acquisition of the shuttle
vector. The ability to transform and manipulate C.
trachomatis using a complementation based vector is an
important advance that opens up the field of Chlamydia
research.
Transformation of Chlamydia trachomatis
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brief heating can be induced to take up foreign DNA [36].
Therefore we initially used such a protocol, developed for E. coli,
to attempt transformation of gradient purified C. trachomatis L2/
434/Bu EBs and selected transformants with 10 units/ml
penicillin. However, we found that heat shock was not necessary
and that the whole transformation protocol could be achieved at
room temperature (RT) simply by gently mixing EBs, vector
DNA and McCoy cells in CaCl2/Tris buffer. This protocol is
described in the Materials and Methods and the selection
procedure is described in Table S1. For selection our reasoning
was to allow recovery of transformants, without penicillin
selection in the first round of infection (developmental cycle)
and then apply selection with penicillin initially at 10 units/ml (10
units = 6 mg penicillin). After three rounds of selection, all the
untransformed penicillin-inhibited C. trachomatis were lost and the
culture was overgrown by penicillin-resistant transformants that
appeared to grow with similar kinetics and inclusion morphology
as the parental strain. It was possible to increase the concentra-
tion of penicillin to 20 and 100 units/ml at passages 3 and 4 to
speed up the selection process. In each experiment regular
observation of the cultures under phase contrast microscopy
allows some flexibility in deciding precisely when the next passage
is needed, taking into account the size, form and number of
inclusion bodies observed at each stage.
Figure 1. Map of the shuttle vector pBR325::L2. The inner circle represents the plasmid pL2 from C. trachomatis L2/434/Bu (blue) and the vector
sequences of pBR325 (red). The coding sequences and their direction of transcription are represented by the boxes of the outer circle. The b-
lactamase (bla), chloramphenicol acetyl transferase (cat) and inactivated tetracycline resistance gene (Dtet) are as indicated, as are key restriction
endonuclease cleavage sites.
doi:10.1371/journal.ppat.1002258.g001
Transformation of Chlamydia trachomatis
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The frequency of transformation, defined as the proportion of
EBs or trypsinised cells receiving the shuttle vector DNA and
still keeping the ability to start chlamydial proliferation, is a
parameter that cannot be measured. The efficiency of recovery
is dependent on the percentage of the transformed EBs present
in the total population of EBs after each stage of selection. Each
passage is performed by infecting cell cultures with cell lysates
from the previous passage (see Materials and Methods, and
Table S1). Following lysis of the McCoy cells, the untrans-
formed Chlamydia, present as non-infectious RBs, fail to passage.
Thus only transformed EBs and a diminishing number of carry-
over untransformed EBs infect new host cells. The recovery
increases with each passage until only transformed Chlamydia
remain.
The pBR325::L2 transformed C. trachomatis L2/434/Bu strain
was plaque purified (x3), expanded, and EBs and RBs were
purified for detailed characterization. Southern blotting of
chromosomal DNA purified from EBs with a vector probe (b-
lactamase gene) and a chlamydial plasmid probe proved that
transformation had occurred and revealed no changes in either the
E. coli vector (pBR325) or the L2 plasmid (pL2), although by these
passages the endogenous chlamydial plasmid had been eliminated
from the transformed strain (Figure 2). There was no evidence for
recombination/integration of the transforming plasmid with the
recipient C. trachomatis chromosomal DNA.
Properties of pBR325::L2 transformed C. trachomatis L2/
434/Bu
The copy number of pBR325::L2 was similar to that of the
endogenous pL2 as accurately measured by qPCR (Figure S1).
To investigate the effects of transformation by plasmid
pBR325::L2 on the strain C. trachomatis L2/434/Bu, we compared
the growth characteristics of the parental strain and the transformed
strain with or without penicillin selection. These data are summarized
in Figure 3 and clearly show that the parental strain (L2) grows well in
McCoy cells, as previously demonstrated, and there was no recovery
of infectious EBs in the presence of penicillin when it was added at 10
units/ml from the start of the developmental cycle.
By contrast, the transformed strain grew in both the presence (10
units/ml) and absence of penicillin (up to 8 passages) giving similar
recoveries of infectious EBs at the end of developmental cycle.
Nevertheless the presence of a large transforming plasmid
(pBR325::L2) has a measurable effect and the developmental cycle
was lengthened and the yield slightly reduced compared to the
untransformed C. trachomatis L2/434/Bu. Transmission electron
microscopy of infected cells at late stages of the developmental cycles
show no obvious phenotypic differences for transformed or
untransformed C. trachomatis in the absence of penicillin but in the
presence of penicillin untransformed C. trachomatis produced large
aberrant RBs whereas transformed C. trachomatis inclusions appeared
normal (Figure S2).
Figure 2. Southern blot of C. trachomatis L2/434/Bu transformed by plasmid pBR325::L2. Equal amounts of C. trachomatis DNA were
loaded in each gel track, the DNA is uncut (track 1) or has been digested to completion with Bam HI (track 2) or Nde I (track 3). (A) DNA from wild type
(untransformed C. trachomatis L2/434/Bu) was probed with the complete plasmid sequence pL2. (B) DNA from the transformed strain also probed
with pL2. (C) DNA from the transformed strain probed with the complete b-lactamase gene sequence (generated by PCR). The wild type pL2 plasmid
(7.5 kb) carries a unique Bam HI restriction site (which is used as the cloning site for insertion into the vector pBR325) but no Nde I site. The bands in
tracks 1 and 3 in panel A represent various forms of the plasmid pL2. The recombinant plasmid pBR325::L2 is ,13.5 kb, thus digestion with Bam HI
releases the pBR325 vector (6 Kb – hybridizing to the bla probe in (C) and the chlamydial plasmid pL2 (7.5 kb – hybridizing to pL2 probe in panel B).
The recombinant plasmid (pBR325::L2) carries a unique Nde I site (located in pBR325) and digestion with this enzyme linearises the vector at 13.5 kb;
this band is detected with both hybridization probes (track 3 panels B and C).
doi:10.1371/journal.ppat.1002258.g002
Transformation of Chlamydia trachomatis
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The vector was recovered from pBR325::L2- transformed C.
trachomatis L2 by genomic DNA preparation and analysed by direct
sequencing. These data showed no evidence for the presence of
the original pL2 and also confirmed that there were no
rearrangements or recombination events with pL2 or within the
pBR325::L2 vector, although there were a few base changes from
the sequences deposited in the database for the original pBR325
vector (Figure S3). These were attributable to errors in the original
sequencing and annotation rather than adaptive mutations or
subsequent transformation of the DNA in to E. coli. Analysis of
multiple colonies carrying the recovered pBR325::L2 from E. coli
by mini-plasmid preparation and restriction digestion showed they
were all clonal and appeared to be unchanged from the
transforming vector. One of these recovered plasmids was also
sequenced and was identical to the sequence obtained direct from
the transformed C. trachomatis.
Immunoblotting of purified EBs and RBs with commercially
available antibodies (Figure S4) showed the presence of both b-
lactamase and chloramphenicol acetyl transferase enzymes
consistent with the observation that pBR325::L2- transformed C.
Figure 3. Growth characteristics of C. trachomatis L2 and C. trachomatis L2 transformed by pBR325::L2. (A) C. trachomatis L2/434/Bu, (B) C.
trachomatis L2/434/Bu transformed by shuttle vector pBR325::L2. McCoy cells in a 24 well tissue culture tray grown to confluence were infected with
C. trachomatis at MOI = 1 and were cultured without (-PEN) and with (+PEN) penicillin G at 10 units/ml. The yield of C. trachomatis (IFU) per culture or
single well is shown on the y – axis and time of sampling post infection is shown on the x –axis. The experiments were repeated in quadruplicate and
standard error bars are shown for each sample point.
doi:10.1371/journal.ppat.1002258.g003
Transformation of Chlamydia trachomatis
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trachomatis L2 was, in contrast to the untransformed C. trachomatis
L2, resistant to penicillin up to 100 units/ml and able to grow in
medium containing chloramphenicol concentrations up to 3 mg/
ml (data not shown).
Interestingly, both the processed and mature forms of b-
lactamase were detectable by immunoblotting in EBs showing that
the signal peptide [37] was functional in C. trachomatis and the pre-
protein was cleaved completely in RBs (Figure S4A). Chloram-
phenicol acetyl transferase levels (as assessed by immunoblot) were
the same in both RBs and EBs (Figure S4B).
The transformed C. trachomatis L2 grew under penicillin selection
and whilst the presence of b-lactamase, as shown by Western
blotting, indicated that resistance to penicillin is likely through the
mechanism of action of this enzyme, it did not prove that the
enzyme is active. Thus to prove formally that the resistance to
penicillin was indeed due to acquisition of an active b-lactamase,
purified RBs (the actively growing form of C. trachomatis) were
assayed for b-lactamase activity. Figure 4 shows that pBR325::L2-
transformed C. trachomatis RBs have b-lactamase activity whereas
RBs from the untransformed parental strain do not.
These results, taken together, established that pBR325::L2
could be selected from a background of untransformed C.
trachomatis and this vector could also replicate in E. coli, therefore
providing the basis of a functional shuttle vector. They showed
proof of principle that the functions for retaining and replicating
the plasmid in C. trachomatis were unaffected in the shuttle vector
and we have established that standard E. coli promoters for both b-
lactamase and chloramphenicol acetyl transferase operate in C.
trachomatis. Further, the b-lactamase is active and the type 1 signal
peptidase mechanism from C. trachomatis [38] is able to cleave the
b-lactamase precursor to a mature form of the correct molecular
weight in RBs, the actively growing form of the micro-organism.
Figure 4. Purified, transformed RBs have b – lactamase activity. In Panel A equal amounts of purified RBs (measured by qPCR of the genome)
from transformed C. trachomatis L2/434/Bu and the wild–type parental C. trachomatis L2/434/Bu were assayed for b – lactamase activity. In Panel B
equal amounts of E. coli and E. coli transformed with pBR325::L2 were used as controls to verify the assay. Hydrolysis of Nitrocefin is measured in
pH 7.0 buffer by absorbance at 486 nm over 60 min. Nitrocefin is a chromogenic b – lactamase substrate.
doi:10.1371/journal.ppat.1002258.g004
Transformation of Chlamydia trachomatis
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In our experiments deriving a transformation frequency as a
percentage of EBs receiving vector DNA is not a relevant measure
and we have no means of measuring how many survive selection in
the first round of culture. We considered it might be possible to do
this if we had a marker such as green fluorescence that we could
use to identify live transformed Chlamydia.
Expression of the green fluorescent protein in C.
trachomatis L2/434/Bu
To show that the transformants obtained in the first series of
experiments were useful for general application and not just the
outcome from a serendipitous choice of a single, vector
configuration (pBR325::L2) it was essential to repeat the work
but with more than one (and different) marker. For this purpose
we chose the mutated plasmid from the Swedish new variant
which has a characteristic 377 bp deletion in CDS1 and a 44 bp
duplication in the 59 terminus of CDS3 [8]. This plasmid was
cloned into an E. coli vector able to express the GFP. The complete
plasmid map of the shuttle vector carrying the mutated plasmid
from SW2 is shown in Figure 5.
Plasmid pGFP::SW2 contains a b-lactamase gene together with
a red-shifted green fluorescent protein gene fused to the
chloramphenicol acetyl transferase gene under control of a
neisserial promoter. The map of the original plasmid
Figure 5. Map of the plasmid vector pGFP::SW2. The inner circle represents the plasmid pSW2 from C. trachomatis SW2 (blue) and the vector
sequences (red). The coding sequences and their direction of transcription are represented by the boxes of the outer circle. Some key restriction
endonuclease cleavage sites used in the construction of this vector are indicated on the inner circle. The cat gene is fused with RSGFP (shaded green)
and expressed by a promoter derived from Neisseria meningitidis (nmP); the direction of transcription of this promoter is designated by the arrow.
doi:10.1371/journal.ppat.1002258.g005
Transformation of Chlamydia trachomatis
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pRSGFPCAT that provided the fused rsgfp-cat cassette including
the neisserial promoter is shown in Figure S5.
E. coli cells transformed with pRSGFPCAT are resistant to
penicillin and chloramphenicol and fluoresce green under blue
illumination (data not shown).
The plasmids and DNA used to make this final shuttle vector
(pGFP::SW2) are summarized in Figure S6. The complete
sequence and list of features for pGFP::SW2 are summarized in
Figure S7.
Transformation of C. trachomatis L2/434/Bu with pGFP::SW2
was successfully achieved on six occasions and yielded a penicillin-
resistant strain that had green fluorescent inclusions (Figure 6).
Green fluorescent inclusions became visible at 24 h post infection,
once the transformants had been selected by multiple passages;
however, we were unable to observe green fluorescent inclusions in
the first developmental cycle post-transformation.
The green fluorescent protein is expressed as a fusion protein with
the chloramphencol acetyl transferase (GFPCAT). To show that the
fluorescence observed in inclusions was derived from the GFPCAT
fusion protein, transformed Chlamydia were immunoblotted with
anti-GFP monoclonal antibodies as shown in Figure S8.
Transformation of plasmid-free C. trachomatis with
pGFP::SW2 restores the ability to biosynthesise glycogen
The ability to stain for the presence of glycogen in chlamydial
inclusions is a property that has been linked to the presence of the
plasmid although it has not been possible to prove formally the
association as no system has previously existed for the introduction
of plasmids into C. trachomatis [21]. The C. trachomatis L2 (25667R)
strain is plasmid-free and not able to accumulate glycogen. We
were unsure whether it would be possible to transform this strain
as it was plasmid-free and may have lost the ability to retain the
plasmid. Nevertheless, we attempted transformation of this C.
trachomatis L2 strain with the vector pGFP::SW2 and obtained
stable penicillin-resistant transformants that had green fluorescent
inclusions. However, transformation of C. trachomatis L2 (25667R)
strain with the basic cloning plasmid pSP73 alone did not yield
transformants showing that the chlamydial plasmid (pSW2) was
necessary to provide the replication functions of the shuttle vector
pGFP::SW2 in C. trachomatis [8,19]. We were able to recover the
intact pGFP::SW2 vector from transformed C. trachomatis L2
(25667R) by genomic DNA preparation and re-transform the
DNA into E. coli. Southern blotting of DNA extracted from
transformed plasmid-free C. trachomatis L2 (25667R) confirmed the
presence of pGFP::SW2 (Figure 7) and proved that transformation
had occurred.
The pGFP::SW2-transformed C. trachomatis L2 (25667R) had
inclusions which stained positive for glycogen (Figure 8). This
observation confirms that glycogen biosynthesis is a trait that is
dependent on the presence of the chlamydial plasmid. Every
inclusion from the pGFP::SW2-transformed C. trachomatis L2
(25667R) stained for glycogen, demonstrating stable transforma-
tion at the individual level as well as the population level (as shown
by the Southern blots).
Figure 6. Green fluorescent inclusions in McCoy cells infected with C. trachomatis L2/434/Bu transformed with pGFP::SW2.
Untransformed C. trachomatis L2/434/Bu (control) and C. trachomatis L2/434/Bu transformed by pGFP::SW2 were grown on coverslips for two days
before fixing in 4% formaldehyde (diluted in DPBS). Panel A shows untransformed C. trachomatis L2/434/Bu under white light (arrows indicate
inclusions). Panel B is the same image under blue light. Panel C shows C. trachomatis L2/434/Bu transformed with plasmid pGFP::SW2 under white
light, and panel D is the same field under blue light. The scale bar represents 20 mm.
doi:10.1371/journal.ppat.1002258.g006
Transformation of Chlamydia trachomatis
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Conclusions
1. We have developed a simple and reproducible genetic
transformation protocol for C. trachomatis based on calcium
chloride treatment of EBs.
2. We have designed a shuttle vector based on the 7.5 kb
chlamydial plasmid and the E. coli plasmid pBR325. This
vector replicates in both C. trachomatis and E. coli and selection is
based on penicillin resistance.
3. C. trachomatis L2/434/Bu transformed by the shuttle vector
pBR325::L2 shows similar growth characteristics and inclusion
formation as the untransformed strain.
4. We have developed a second smaller shuttle vector
pGFP::SW2 that conveys penicillin resistance through beta-
lactamase expression and that also expresses the GFP.
5. C. trachomatis L2/434/Bu transformed with pGFP::SW2
produces green fluorescent inclusions.
6. Transformation of a plasmid-free strain of C. trachomatis L2
(25667R) with pGFP::SW2 generates green fluorescent inclu-
sions and also restores the glycogen staining phenotype
confirming that this property is a plasmid-dependent property.
7. The development of a simple and reproducible transformation
method will open the way to a better understanding of
chlamydial genetics and could lead to the development of new
approaches to chlamydial vaccines and therapeutic interven-
tions aimed at modulating chlamydial pathogenesis.
Materials and Methods
Microscopy
Cells in culture and cells infected with C. trachomatis L2 were
routinely visualized by phase contrast microscopy using a Nikon
eclipse TS100 inverted microscope with fluorescence accessories.
Fluorescence images were captured using a Leica DMRB
microscope to visualize the expression of GFP in McCoy cells
infected by pGFP::SW2-transformed C. trachomatis L2. Counting of
inclusion forming units (IFU) to quantify chlamydial infectivity was
performed on serial dilutions of C. trachomatis L2 in monolayers of
McCoy cells grown in 96 well trays. For this assay inclusions were
immunostained as previously described for C. abortus [39]. For
transmission EM studies McCoy cells infected with C. trachomatis
L2 at a multiplicity of infection (MOI) of 1 were grown in 6 well
trays and 48 h post infection were fixed with 3% glutaraldehyde in
0.1% cacodylate buffer, processed as previously described [40] and
photographed using an Hitachi H7000 electron microscope.
E. coli strains, recombinant plasmids and genetic
manipulations
E. coli strain DH5a [41,42] and its derivative strain E. coli
‘Top10’ from Invitrogen were used for the basic cloning and
construction of vectors pRSGFPCAT and pGFP::SW2. The
vector pBR325::L2 was constructed by ligation of pL2 cleaved
by Bam HI from plasmid PDCPB [33] (this vector is equivalent to
pBR322::L2) into Bam HI cleaved pBR325 (GenBank: L08855.1),
this cloning was performed in E. coli strain HB101. The original
preparation of the plasmid pBR325::L2 DNA (used to transform
C. trachomatis L2 EBs) was performed in E. coli strain HB101, but all
subsequent plasmid manipulations for transformation were
performed using E. coli GM 2163. This strain is mutated for
Dam, Dcm and Mcr methylation systems and was available from
New England Biolabs (Cat. no. #E4105S). Plasmid pGFP::SW2
(Figure 5) was constructed from the C. trachomatis SW2 plasmid
pSW2, pSP73 and pRSGFPCAT. The complete cloning strategy
is summarised in Figure S6. Plasmid pRSGFPCAT is a small in-
house vector based on a pUC origin of replication and carrying
Figure 7. Southern blot of C. trachomatis L2 (25667R) transformed by plasmid pGFP::SW2. Southern hybridization analyses of plasmid-free
C. trachomatis L2 (25667R) (abbreviated as L2P-) and C. trachomatis L2 (25667R) transformed with plasmid pGFP::SW2 (in short L2P-/pSW2). Six
chlamydial genomic DNA samples were loaded on the gel in pairs together with HyperLadder I (5 ml) from BIOLINE (Cat No. BIO-33025). The agarose
gel image was taken before DNA transfer (A). The DNA blot was first hybridized with the pSW2 probe (B), and then stripped and re-probed with the
GFP probe (C) or an ompA probe (D). Bam HI digestion of pGFP::SW2 created 3 fragments: 7169 bp (containing pSW2 probe sequence), 2925 bp and
1445 bp (containing GFP probe sequence). Bgl II digestion of pGFP::SW2 created 4 fragments: 5555 bp (containing the pSW2 probe sequence),
3625 bp (containing the GFP probe sequence), 1693 bp and 666 bp. When the C. trachomatis L2 genomic DNA (similar to L2P-) was digested with
Bam HI or Bgl II, the fragment containing ompA sequence was 8837 bp (Bam HI digestion) or 5518 bp (Bgl II digestion). Southern hybridization using
the pSW2 probe or the GFP probe showed hybridization signals at expected positions in all L2P-/pGFP::SW2 samples (uncut or digested); whilst no
hybridization signal, as expected, was detected in all L2P- samples (uncut or digested) (B) and (C). Southern hybridization using the ompA probe
showed that the hybridization signals were similar in L2P- and L2P-/pGFP::SW2 samples (uncut or digested) (D).
doi:10.1371/journal.ppat.1002258.g007
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the cat gene fused to RSGFP and under the control of a neisserial
promoter that is constitutively expressed in E. coli (refer to Figure
S5 for sequence details). Briefly, the Bam HI fragment of pSW2
(GenBank: FM865439.1 - obtained by gel extraction from a C.
trachomatis SW2 total genomic DNA Bam HI digestion) (Figure S6
panel A) was cloned into the unique Bam HI site of plasmid pSP73
(Figure S6 panel B) to give plasmid pSP73::SW2 (Figure S6 panel
C). The Pst I/Sal I fragment of pRSGFPCAT (Figure S6 panel D)
was then cloned into Pst I/Sal I backbone of pSP73 allowing
selection of ampicillin resistant, chloramphenicol resistant green
fluorescent colonies.
Ethics statement
All genetic manipulations and containment work was approved
under the UK Health and Safety Executive Genetically Modified
Organisms (contained use) regulations 2000 notification no
GM57,10.1 entitled ‘Genetic transformation of Chlamydiae’.
Cell culture and propagation of C. trachomatis strains
McCoy cells were used for propagation of C. trachomatis and for
the transformation studies. Two strains of C. trachomatis were used
as recipient strains for transformation in this study: C. trachomatis
L2/434/Bu (ATCC VR-902B) which carries a 7.5 kb plasmid
(pL2) and C. trachomatis L2 (25667R) which has no plasmid [15].
Both strains were confirmed as pure, clonal isolates by 3 rounds of
plaque purification and, together with the McCoy cells, were
regularly tested for mycoplasma contamination by fluorescence
microscopy using Hoechst no. 33258 staining and by VenorGem
Mycoplasma PCR detection (Minerva Biolabs, Berlin, Germany)
according to the manufacturer’s instructions. The McCoy cells
were grown in Dulbecco’s modified Eagles’ medium (DMEM)
supplemented with 10% fetal calf serum (FCS). Cell concentra-
tions were determined by staining with Trypan Blue and counting
in a haemocytometer. Cells were infected with C. trachomatis by
overlay of the inoculum for 1 h in medium containing cyclohex-
imide (1 mg/ml) and gentamicin (25 mg/ml). On completion of the
developmental cycle and immediately prior to host cell lysis,
infected monolayers were detached with trypsin/EDTA buffer
(from Invitrogen, Cat. # 25300-054) and EBs were harvested in
DMEM containing 10% FCS at 3,000 g for 10 min. The C.
trachomatis-infected cell pellet was suspended in a solution of 10%
PBS in water and homogenized in a Dounce homogenizer to
break open the cells and release the EBs. Cell debris was removed
by centrifugation at 250 g for 5 min and the supernatant
containing partially purified EBs was mixed with an equal volume
of phosphate/sucrose buffer (16 mM Na2HPO4 pH 7.1 and
0.4 M sucrose, abbreviated as 4SP), and was stored at 280uC.
Plaque assay for infectivity assay and for clonal
purification of EBs and RBs
The C. trachomatis strains were plaque purified as previously
described [31,43]. Briefly a single plaque was picked, cultured and
purified to clonality by two further rounds of plaquing. The
plaque-purified Chlamydia were then used to make stock prepara-
tions. Large scale cultures were prepared for the production of EBs
and RBs which were purified by two cycles of Urografin (Schering
Healthcare, UK) density gradient centrifugation as previously
described [31].
Figure 8. Acquisition of the plasmid pGFP::SW2 restores the ability of plasmid-free C. trachomatis L2 (25667R) to synthesize
glycogen. The presence of glycogen within inclusions was detected by iodine staining of cells on coverslips. (A) McCoy cells control, (B) C.
trachomatis L2 (25667R) in McCoy cells, (C) C. trachomatis L2/434/Bu in McCoy cells, (D) pGFP::SW2- transformed C. trachomatis L2 (25667R) in McCoy
cells. The scale bar represents 20 mm.
doi:10.1371/journal.ppat.1002258.g008
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Genetic transformation of C. trachomatis
A simple protocol was developed where C. trachomatis L2 EBs
were first mixed with plasmid DNA and then used to infect freshly
trypsinised McCoy cells (MOI = 2.5). The preparation of EBs,
vector DNA and cells followed by the transformation protocol is
described in detail below.
1. Preparation of EBs for transformation: McCoy cells were
grown in 66T75 flasks, and infected with C. trachomatis L2 in fresh
medium (DMEM + 10%FCS) containing 1 mg/ml of cyclohexi-
mide, and grown in 37uC, 5% CO2 incubator for 2 days at an
MOI = 2 giving ,90% cells infected. The cells were bulk
harvested using cell scrapers, and then spun at 3500 rpm for
10 min. The cell pellet was saved, resuspended in 1 ml of cold
10% PBS, and transferred into a bijoux tube with glass beads. The
cells were then lysed by vortexing for 1 min. The cell debris was
removed by spinning at 1000 rpm for 5 min. The supernatant was
saved (,1 ml) and mixed with 1 ml of 4SP. The inocula were
divided into 100 ml aliquots and stored at 280uC.
2. The vector DNA was extracted from overnight E. coli cultures
(GM2163 strain) using the PureYield Plasmid Midiprep System
(Promega Cat. No. A2492). The quality and the concentration of
the DNA were evaluated by agarose gel electrophoresis and
NanoDrop 1000 Spectrophotometer (from Thermo Scientific).
The DNA was used at concentration ,0.5–1 mg/ml.
3. McCoy cells were prepared for transformation when cells
were ,70% confluent in a T75 flask, the medium was removed
and the cells were washed twice with 5 ml Dulbecco’s PBS (DPBS)
(from Invitrogen, Cat. # 14190-094). Then 2 ml Trypsin/EDTA
buffer was added to cover the cells. Trypsinisation was allowed to
proceed at RT for 5 min and when the cells were released from
the flask, 10 ml of medium was added with a pipette, and the
medium was washed up and down with the pipette to release the
remaining cells and to break up clumps. The cells were transferred
to a plastic universal and spun in a bench top centrifuge (Beckman
Coulter Allegra X-15R) at 1000 rpm for 5 min, the medium was
removed and the pellet briefly rinsed and then resuspended in
5 ml DPBS and pelleted again at 1000 rpm for 5 min. The DPBS
buffer was discarded and cells resuspended in CaCl2 buffer for
transformation.
4. Transformation is performed as follows: 10 ml Chlamydia EBs
(16107 IFU) and 10 ml plasmid DNA (6 mg) were mixed in a total
volume of 200 ml CaCl2 buffer (10 mM Tris pH 7.4 and 50 mM
CaCl2) and then incubated for 30 min at room temperature.
Freshly trypsinised McCoy cells (46106), resuspended in 200 ml
CaCl2 buffer were then added to the plasmid/EB mix and
incubated for a further 20 min at room temperature with
occasional mixing. 100 ml of this mixture was then added to a
single well in a six well tray together with 2 ml of pre-warmed
DMEM + 10% FCS. The cells were allowed to settle and
incubated at 37uC in 5% CO2 for 2 days without cycloheximide or
penicillin. The infected cells from each well were harvested
individually by scraping cells with a 1 ml filter tip and then lysed
by vortexing with glass beads. The cell debris was removed by
spinning at 1000 rpm for 5 min. The supernatant was saved
(,2 ml) and mixed with 2 ml of 4SP and stored in 280uC freezer
(this was called T0).
5. Passage and selection. The T0 inocula were used to infect
McCoy cells in a T75 flask (passage 1). Potential transformants
were grown in medium containing cycloheximide (1 mg/ml) and
selected with 10 units/ml of penicillin G (Sigma product no.
P3032). Under these conditions, most inclusions were large and
vacuolar as previously described [6]. Chlamydia were grown for two
days before harvesting as ‘T1’ and this was used to infect McCoy
cells as passage 2 in a T25 flask and selected with 10 units/ml of
penicillin. Passaging was continued for 2–4 times in T25 flasks with
10 units/ml of penicillin until only normal inclusions were
recovered. The passage and selection procedures are summarized
in Table S1.
Genomic DNA extraction from C. trachomatis strains
The genomic DNA of C. trachomatis L2, C. trachomatis L2 (25667R)
and pBR325::L2- transformed C. trachomatis L2 (or L2, L2P- and
L2/pBR325::L2 in short) were extracted from Chlamydia inocula
(collected from infected McCoy cells in T75 flasks) using Wizard
Genomic DNA Purification Kit (Promega, Cat. No. A1120). The
genomic DNA of pGFP::SW2- transformed C. trachomatis L2 and
transformed C. trachomatis L2 (25667R) (or L2/pGFP::SW2 and
L2P-/pGFP::SW2 in short) was extracted from Chlamydia inocula
(collected from a well of infected McCoy cells in 6-well tray) using
NucleoSpin Tissue (Fisher Scientific, Cat. No. NZ74095250). The
genomic DNA extracted from transformed C. trachomatis (L2/
pBR325::L2, L2/pGFP::SW2 or L2P-/pGFP::SW2) were used for
sequencing and the transformation of E. coli to recover the shuttle
plasmids.
Southern blotting
Restriction endonuclease digests of chlamydial genomic DNA
were separated on agarose gels and then transferred to membranes
using standard techniques [26]. TheDNAused as probes in Figure 2
were either a ,550 bp PCR amplicon for the b-lactamase gene
using primer pair AmpF 59-TTACCAATGCTTAAT-39 and
AmpR 59-TACTCACCAGACACAG-39) using pBR325::L2 as
template or the whole recombinant chlamydial plasmid (pL2)
released from the cloning vector pBR325::L2 by complete digestion
with BamHI (the insert was separated from the cloning vector by gel
electrophoresis and the 7.5 kb fragment then eluted). DNA
fragments were labeled with [a-32P]deoxy-CTP using a random
primer labeling kit (Promega). The labeled products were purified
by gel filtration on Sephadex G50. Membranes were pre-
hybridized, hybridized overnight and then washed according to
the manufacturer’s standard conditions at 65uC. Dried membranes
were exposed to Kodak XAR-5 film. In Figure 7 blots were probed
with nonradioactive, digoxigenin-11-dUTP-labeled probes (Ran-
dom primed DNA labelling) and chemiluminescence detection with
CSPD (Roche Diagnostics Ltd., Product No. 11 585 614 910). The
gfp probe was a 739 bp Bam HI/Bgl II fragment from pGFP::SW2,
which annealed to a 1445 bp fragment of Bam HI digested
pGFP::SW2 or a 3625 bp fragment of Bgl II digested pGFP::SW2.
The pSW2 probe template was a 2518 bp Eco RI fragment from
pGFP::SW2 (between pSW2 CDS4 and CDS7), which annealed to
a 7169 bp fragment of Bam HI digested pGFP::SW2 or a 5555 bp
fragment of Bgl II digested pGFP::SW2. The ompA probe template
was a 1022 bp PCR product from C. trachomatis L2 (25667R) using
primers PCTM3 (59- TCCTTGCAAGCTCTGCCTGTGGG-
GAATCCT-39) and NR1 (59-CCGCAAGATTTTCTAGATT-
TC-39) based on the C. trachomatis L2/434/Bu ompA sequence, this
probe annealed to a 8837 bp fragment of BamHI digested genomic
DNA or a 5518 bp fragment of Bgl II digested genomic DNA.
pBR325::L2 copy number determination
McCoy cells grown to confluence in 96 well trays were infected
with C. trachomatis L2/434/Bu transformed by pBR325::L2 at
MOI = 1.0. EBs were allowed to adsorb to cells for 1 h at 37uC;
cells were then washed with PBS to remove any residual
unadsorbed EBs. The infected cells (performed in quadruplicate)
were overlaid with 100 ml culture medium and incubated at 37uC
in 5% CO2. At 65 h post infection, when the developmental cycle
had completed, samples were stored (after snap freezing) at
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280uC. For penicillin - treated cultures, medium containing 10
units/ml penicillin G was added at the time of infection.
Chromosomal and plasmid DNA was extracted in a microplate
format following a well described protocol. The residue was then
resuspended in 100 ml nuclease-free water. Samples were diluted 1
in 100 prior to quantitative real time polymerase chain reaction
(qPCR) analysis. A quantitative real-time PCR protocol was used
to determine the absolute number of chlamydial plasmids and
genomes in samples using 59- exonuclease (TaqMan) assays with
unlabelled primers andcarboxyfluorescein/carboxytetramethylr-
hodamine (FAM/TAMRA) dual-labeled probes as has been
described previously.
Immunoblotting for detection of b-lactamase,
chloramphenicol acetyl transferase and green
fluorescent protein
Proteins from purified EBs and RBs were run on 10% SDS
PAGE gels and the proteins were electroblotted onto a BioRad
Immun-Blot PVDF (polyvinylidene difluoride) membrane for 1 h
at 15 V. The membrane was incubated in a solution of PBS
supplemented with 0.05% Tween-20 (PBS-T) and 5% dried milk
for 30 min at room temperature. Commercially available
antibodies that recognize the enzymes b-lactamase (AbCam
mouse monoclonal Cat. No. ab12251) and chloramphenicol
acetyl transferase (Sigma anti-CAT antiserum from rabbit product
no. C9336) were used at a concentration of 10 mg/ml, the anti-
GFP mouse monoclonal antibodies (Roche Cat no. 11814 460
001) were used at 0.4 mg/ml in a solution of PBS-T supplemented
with 1% dried milk, and incubated with the membrane for 1 h at
RT. Following extensive washing with PBS-T the membrane was
incubated for 1 h at room temperature with horseradish
peroxidase-conjugated goat- anti-mouse or goat- anti-rabbit
antibody (BioRad cat nos. 172-1011 and 172-1019) at the
recommended dilution. After further washing with PBS-T the
membrane was incubated in Pierce ECL Western Blotting
Substrate (Thermo Scientific product no. 32106) as described by
the manufacturer’s instructions and exposed to Kodak BioMax
XAR film.
Nitrocefin assays for b-lactamase
Nitrocefin changes from yellow to red in the presence of b-
lactamase, therefore it can be used as an indicator of b-lactamase
activity. A standard Nitrocefin assay was set up in 1 M Phosphate
buffer (K2HPO4.3H20; KH2PO4) pH 7.0 using Nitrocefin
(0.5 mg/ml) as described by the manufacturer (Calbiochem,
Darmstadt, Germany). Equal amounts of gradient-purified C.
trachomatis RBs (as determined by qPCR assay) from pBR325::pL2-
transformed C. trachomatis L2/434/Bu and the wild–type parental
C. trachomatis L2/434/Bu, and E. coli and pBR325::pL2-
transformed E. coli were used in this assay and samples were
taken at 5 min intervals for OD readings at 486 nm.
Time course of infection
McCoy cells grown to confluence in 24 well trays were infected
with C. trachomatis at MOI= 1. EBs were allowed to adsorb to cells
for 1 h at 37uC and the infected cells were washed with PBS to
remove any non-adsorbed EBs. The cells were then overlaid with
culture medium or culture medium containing penicillin G at 10
units/ml and incubated at 37uC in 5% CO2. The infection was
stopped at 8-hourly time points (8, 16, 24, 32, 40, 48, 56, 64 and
72 h) by scraping up the cells and vortexing with glass beads. The
samples were then rapidly frozen and stored at 280uC.
Iodine staining of inclusions
C. trachomatis strains were cultured in McCoy cells on coverslips.
Briefly, infected cells bearing C. trachomatis inclusions were washed
with PBS and then fixed to coverslips with ice-cold methanol. The
coverslips were stained with 5% iodine stain (containing both
potassium iodide and iodine in 50% ethanol) for 10 min. The stain
was then changed for 2.5% iodine stain for 10 min and mounted
in 5% iodine stain in glycerol (1:1) for photomicroscopy.
Supporting Information
Figure S1 Quantification of plasmid and chromosomal
copies in pBR325::L2- transformed C. trachomatis L2/
434/Bu. The Chlamydia were grown in the absence (-PEN) and
presence of penicillin (+PEN at 10 units/ml). The graph shows the
absolute number of chromosomal and plasmid DNA copies in
cultures from 96 well plates harvested at 64 h post-infection (y –
axis). These data were generated by qPCR from four separate
experiments and the standard error bars are indicated. The
plasmid copy number (16 – 19) is similar under selective and non-
selective conditions.
(TIF)
Figure S2 Effects of penicillin at 48 h post infection by
transmission electron microscopy.Mature C. trachomatis L2/
434/Bu inclusions at 48 h post infection are shown in the absence
(A) and presence (B) of penicillin (10 units/ml). Mature C. trachomatis
L2/434/Bu transformed by pBR325::L2 inclusions at 48 h post
infection are shown in the absence (C) and presence (D) of penicillin.
C. trachomatis L2/434/Bu transformed by pBR325::L2 is unaffected
by penicillin treatment. The scale bar represents 5 mm, all electron
micrographs were taken at the same magnification.
(TIF)
Figure S3 Plasmid pBR325::L2 features and sequence.
The original pBR325::L2plasmid sequence (13495 bp) was based
on GenBank data. It was created by ligating the L2 plasmid Bam
HI fragment (7499 bp, GenBank: X07547) into the pBR325
cloning vector (5996 bp, GenBank: L08855) Bam HI site. The
whole plasmid was sequenced from total DNA extracted from
pBR325::L2 transformed C. trachomatis L2 and also from plasmid
DNA recovered from E. coli. The changes from the GenBank
sequence were two nucleotide substitutions, two deletions and one
insertion, these changes are all located to the pBR325 vector in
non-coding regions, hence the actual plasmid is one nucleotide
shorter than the predicted sequence.
(DOC)
Figure S4 Expression of b-lactamase and chloramphen-
icol acetyl transferase by EBs and RBs in transformed C.
trachomatis. Equal amounts of proteins from purified EBs and
RBs from C. trachomatis L2/434/Bu (tracks 1 and 2) and C.
trachomatis L2/434/Bu transformed by pBR325::L2 (tracks 3 and
4) were separated by SDS PAGE and immunoblotted with
antisera to b-lactamase panel A and chloramphenicol acetyl
transferase panel B. The two arrows in panel A indicate the
mature and unprocessed forms of b-lactamase. The single arrow in
panel B indicates the presence of chloramphenicol acetyl
transferase.
(TIF)
Figure S5 Plasmid pRSGFPCAT features and sequence.
The plasmid pRSGFPCAT is a small in house vector (2670 bp)
containing the pUC origin and the RSGFP-CAT gene-fusion
under the control of the meningococcal class I protein promoter
(MCIP, designated nmP in Figure 5) from MC50. It was
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constructed by multiple cloning steps. Individual fragments were
generated by PCR (see the table below for the sources of each
fragment).
(DOC)
Figure S6 Map of the vectors used as a basis for
constructing pGFP::SW2. Chlamydial plasmid pSW2 (A -
dark blue) was ligated into the Bam HI site of pSP73 (B - red) to
give intermediate plasmid pSP73::SW2 (C). The Pst I – Sal I
fragment (light blue) from in-house vector pRSGFPCAT (D) was
ligated in to Pst I/Sal I cleaved pSP73::SW2 to give the final vector
pGFP::SW2 (E).
(TIF)
Figure S7 Plasmid pGFP::SW2 features and sequence.
The pGFP::SW2 (11539 bp) was created by inserting the C.
trachomatis SW2 plasmid (7169 bp, GenBank: FM865439.1) Bam
HI fragment into the pSP73 cloning vector (2464 bp, GenBank:
X65333.2) Bam HI site (forming an intermediate construct
pSP73::SW2), then inserting the Pst I/Sal I fragment (RSGFPCAT
cassette) from pRSGFPCAT (2670 bp, to be deposited in
GenBank) into Pst I/Sal I sites of pSP73::SW2 (on pSP73
backbone). The promoter for GFPCAT expression is the
meningococcal class I protein promoter (MCIP, designated nmP
in Figure 5) for outer membrane protein PorA from Neisseria
meningitidis MC50. The plasmids pRSGFPCAT and pSW2, and
the sequences around cloning sites of pGFP::SW2 were verified.
(DOC)
Figure S8 Expression of GFPCAT in E. coli and C.
trachomatis L2/434/Bu transformed by pGFP::SW2.
Protein samples of Chlamydia lysates and E. coli lysates were
separated by 10% SDS PAGE gel and immunoblotted with anti-
GFP monoclonal antibodies (Roche, Cat. # 11 814 460 001).
Tracks 1 and 2 are C. trachomatis L2/434/Bu and C. trachomatis L2/
434/Bu transformed by pGFP::SW2. Tracks 3 and 4 are E.coli and
the same E.coli strain transformed by pGFP::SW2. The GFPCAT
fusion protein is arrowed at 53kDa.
(TIF)
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